- Home
- HYMC vs CTMX Comparison
HYMC vs CTMX Comparison
Compare HYMC & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HYMC
- CTMX
- Stock Information
- Founded
- HYMC N/A
- CTMX 2008
- Country
- HYMC United States
- CTMX United States
- Employees
- HYMC 56
- CTMX N/A
- Industry
- HYMC Precious Metals
- CTMX Biotechnology: Pharmaceutical Preparations
- Sector
- HYMC Basic Materials
- CTMX Health Care
- Exchange
- HYMC Nasdaq
- CTMX Nasdaq
- Market Cap
- HYMC 648.5M
- CTMX 596.2M
- IPO Year
- HYMC N/A
- CTMX 2015
- Fundamental
- Price
- HYMC $7.75
- CTMX $3.23
- Analyst Decision
- HYMC
- CTMX Strong Buy
- Analyst Count
- HYMC 0
- CTMX 5
- Target Price
- HYMC N/A
- CTMX $5.80
- AVG Volume (30 Days)
- HYMC 1.9M
- CTMX 2.8M
- Earning Date
- HYMC 10-28-2025
- CTMX 11-07-2025
- Dividend Yield
- HYMC N/A
- CTMX N/A
- EPS Growth
- HYMC N/A
- CTMX 263.20
- EPS
- HYMC N/A
- CTMX 0.49
- Revenue
- HYMC N/A
- CTMX $141,100,000.00
- Revenue This Year
- HYMC N/A
- CTMX N/A
- Revenue Next Year
- HYMC N/A
- CTMX N/A
- P/E Ratio
- HYMC N/A
- CTMX $6.67
- Revenue Growth
- HYMC N/A
- CTMX 18.01
- 52 Week Low
- HYMC $1.99
- CTMX $0.40
- 52 Week High
- HYMC $9.75
- CTMX $3.91
- Technical
- Relative Strength Index (RSI)
- HYMC 56.21
- CTMX 52.39
- Support Level
- HYMC $6.48
- CTMX $3.21
- Resistance Level
- HYMC $8.26
- CTMX $3.50
- Average True Range (ATR)
- HYMC 0.71
- CTMX 0.23
- MACD
- HYMC -0.11
- CTMX -0.07
- Stochastic Oscillator
- HYMC 40.99
- CTMX 7.43
About HYMC Hycroft Mining Holding Corporation
Hycroft Mining Holding Corp is a gold and silver producer. Its operating mine, the Hycroft Mine, is an open-pit heap leach operation located approximately fifty four miles west of Winnemucca, Nevada.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.